Cancer Markers. Diagnostic and Developmental Significance
Cancer Markers. Diagnostic and Developmental Significance
复制标题
癌症标志物。
DOI：
10.1038/bjc.1981.242
复制
发表时间：
1981
影响因子：
8.8
通讯作者：
M. Moore
中科院分区：
文献类型：
--
作者：
M. Moore
个别肿瘤已经扩大；关于新方法的第四部分较短。介绍了肿瘤治疗的策略、化疗的基本概念和肿瘤临床试验。更多的是强调病人需要“一个敏感和理解的医生”，什么时候治疗，什么时候不治疗，以及在治疗老年人时要克制。图表更清晰了，但关于临床试验类型的令人钦佩的部分可能会因为每种类型都有更多的例子而有所帮助。第二部分的效用，其中药物被单独考虑，已通过纳入药代动力学数据得到改善。之后，VM-26、二溴甘露醇和克鲁酮不再产生这种物质，而vinind -sin和nafoxidine则可以。也许第79页的附加说明，所有的剂量都是针对适合的病人的单药治疗，而关于何时减少剂量的建议应该更明显地显示给粗心的人。关于单个肿瘤的化疗的第三部分现在（更有用）是按字母顺序排列，而不是按肿瘤组排列。尽管有两位作者来自欧洲，但实际上所有临床试验的例子都来自美国。然而，评论很好地平衡了；在结直肠癌中，联合化疗“不能推荐作为常规治疗”，而在卵巢癌中，“没有对照研究明确证明铂类联合化疗优于单药治疗”。关于辅助化疗的部分被与最近数据相匹配的现实主义所缓和。在关于新方法的最后一节中，“免疫疗法”已被“生物反应修饰剂”一节所吸收，其他新章节包括骨髓移植、化学敏感性测试和放射增敏剂。这本书收录了一个大型国际会议（1979年10月举行）的会议记录，该会议由纽约科学院主持，由30家制药公司、国家过敏和传染病研究所以及国家科学基金会赞助。在这次会议上，首次公开了3种不同干扰素的部分氨基酸序列。然而，正如各个领域的专家会立即认识到的那样，这里提出的许多数据已经出现在文献的其他地方。尽管在出版的会议中，我们不情愿地认为重复是司空见惯的，但这本书是有用的，尤其是因为它作为干扰素研究的跨学科纲要，比最近可用的其他专门的干扰素评论更广泛。大约有300个贡献者……
individual tumours) have been expanded; the 4th section on new approaches is shorter. The introduction deals with the strategy of cancer treatment, basic concepts of chemo-therapy and cancer clinical trials. More emphasis is laid upon the patient who needs "a sensitive and understanding physician", when and when not to treat and upon restraint in treating the elderly aggressively. The diagrams are clearer but the admirable section on types of clinical trials might be helped by more examples of each. The utility of the second section, where drugs are considered individually, has been improved by the inclusion of pharmacokinetic data. Ftorafer, VM-26, dibromo-mannitrol and calusterone no longer make it but vinde-sine and nafoxidine now do. Perhaps the rider on p. 79, that all doses are given as for single-agent therapy in fit patients and the advice on when to reduce dosage should be more prominently displayed for the unwary. The third section on the chemotherapy of individual tumours is now (more usefully) in alphabetical order rather than by tumour groups. Despite the fact that two authors are from Europe, vitually all examples of clinical trials are from the United States. However, the comments are nicely balanced; in colorec-tal cancer, combination chemotherapy "can-not be recommended for routine therapy" and in ovarian cancer "controlled studies do not exist to clearly establish the superiority of platinum combinations over single agent therapy". The section on adjuvant chemo-therapy is tempered by a realism which matches the recent data. In the final section on new approaches, "Immunotherapy" has been ingested by a section called "Biological Response Modi-fiers" and other new sections include marrow transplantation, chemosensitivity testing and radiosensitisers. This book comprises the proceedings of a large international conference (held in October 1979) under the auspices of the New York Academy of Sciences and sponsored by 30 pharmaceutical companies, the National Institue of Allergy and Infectious Diseases and the National Science Foundation. At this meeting partial amino-acid sequences of 3 different interferons were disclosed for the first time. However, much of the data presented here has appeared elsewhere in the literature, as specialists in the various fields will immediately recognize. Despite the repetition which we have relucantly come to regard as commonplace amongst published conferences, the book is useful, not least because it serves as a interdisciplinary compendium of interferon research, which is more extensive than other specialized inter-feron reviews which have recently become available. About 300 contributors …